Conestat alfa clinical trials
How each study uses conestat alfa is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the conestat alfa studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2009 | 1 |
| 2012 | 1 |
| 2014 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 6
Pharming Technologies B.V. (6) · University Hospital, Basel, Switzerland (3) · IMMUNOe Research Centers (2) · Bernstein Clinical Research Center (1) · University of Cincinnati (1) · University of Wisconsin, Madison (1)
Often tested with
Tested in the same studies.
Complement C1 Inhibitor Protein (4) · C1 esterase inhibitor (human) (4)
Related medicines
As reviewed, each with the page that says it.
- A recombinant medicine of Complement C1 Inhibitor Protein source
- One of Protease Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test conestat alfa.
- Jul 2027Exploring the Extended Efficacy and Initial Use of RUCONEST® in Managing Neurological Symptoms Linked to Infectious PathogensPhase 4 · IMMUNOe Research Centers
Studies
Open first, then newest update. How each study uses conestat alfa is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 14
- Exploring the Extended Efficacy and Initial Use of RUCONEST® in Managing Neurological Symptoms Linked to Infectious PathogensRecruitingPhase 4IMMUNOe Research CentersNCT07932002Written as Ruconest
- Safety and Efficacy of Conestat Alfa for ACE-Induced AngioedemaNot yet recruitingPhase 3University of CincinnatiNCT06679426Written as Conestat Alfa
- Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Acute Ischemic Cerebral and Renal Events After Transcatheter Aortic Valve ImplantationCompletedPhase 2University Hospital, Basel, SwitzerlandNCT05145283Written as Conestat alfa (Ruconest®)
- Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 InfectionCompletedPhase 2IMMUNOe Research CentersNCT04705831Written as Ruconest
- Treatment of Hereditary Angioedema Prodrome with Recombinant C1-esterase Inhibitor (Ruconest)CompletedPhase 4Bernstein Clinical Research CenterNCT06690047Written as Ruconest
- Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) PatientsCompletedPhase 2Pharming Technologies B.V.NCT01359969Written as rhC1INH
- Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19CompletedPhase 2Pharming Technologies B.V.NCT04530136Written as Ruconest
- Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19TerminatedPhase 2University Hospital, Basel, SwitzerlandNCT04414631Written as Conestat alfa
- RUCONEST® as a Therapeutic Strategy to Reduce the Incidence of Delayed Graft FunctionStatus unknownPhase 1University of Wisconsin, MadisonNCT03791476Written as rhC1INH
- Recombinant Human C1 Esterase Inhibitor in the Prevention of Contrast-induced Nephropathy in High-risk SubjectsCompletedPhase 2University Hospital, Basel, SwitzerlandNCT02869347Written as Conestat alfa
- A Study of the Safety and Immunogenicity of Repeated rhC1INH AdministrationCompletedPhase 2Pharming Technologies B.V.NCT00851409Written as Recombinant Human C1 Inhibitor
- A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 InhibitorCompletedPhase 2Pharming Technologies B.V.NCT02247739Written as Recombinant human C1 inhibitor
- Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary AngioedemaCompletedPhase 2/3Pharming Technologies B.V.NCT00225147Written as Recombinant Human C1 Inhibitor
- Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary AngioedemaCompletedPhase 3Pharming Technologies B.V.NCT00262301Written as recombinant human C1 inhibitor
What changed recently
From the registry's own updates since Oct 18, 2026.